
THURSDAY, May 11, 2023 (HealthDay News) – A gene-targeted personalized vaccine may delay the return of pancreatic cancer according to a small, but promising, trial.The mRNA vaccine, which was tailored to the genetic makeup of each patient's tumor, worked in half of those who received it during 18 months of follow-up, researchers reported May 10 in the journal Nature.Scientists at BioNTech (known for developing a COVID vaccine with Pfizer during the pandemic) and Genentech created the novel vaccine. Experts reacted to the news with cautious hope.“It’s relatively early days,†Dr. Patrick Ott, of the Dana-Farber Cancer Institute in Boston, told the New York Times.“This is the first demonstrable success — and I will call it a success, despite the preliminary nature of the study...